General Announcement::ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide

Issuer & Securities

Issuer/ Manager
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
02-Jun-2025 08:41:29
Status
New
Announcement Sub Title
ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide
Announcement Reference
SG250602OTHRRB2T
Submitted By (Co./ Ind. Name)
Izumi Masuyama
Designation
Associate Director of External Reporting
Description (Please provide a detailed description of the event in the box below)
Takeda and Protagonist Therapeutics, Inc. announced on June 1, 2025 (CST), at American Society of Clinical Oncology (ASCO) Annual Meeting, detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints.

Attachments

ASCO Plenary Presentation Highlighting Full 32-Week Results_0602.pdf
Total size =474K